Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard
Vanguard
The Vanguard Group is an American registered investment advisor based in Malvern, Pennsylvania with over $5.3 trillion in assets under management. It is the largest provider of mutual funds and the second-largest provider of exchange-traded funds in the world after BlackR…
Brokerage firm
A brokerage firm, or simply brokerage, is a financial institution that facilitates the buying and selling of financial securities between a buyer and a seller. Brokerage firms serve a clientele of investors who trade public stocks and other securities, usually through the firm's agent stockbrokers. A traditional, or "full service," brokerage firm usually undertakes more than simply carrying out a stock or bond tr…
TD Ameritrade
TD Ameritrade is a broker that offers an electronic trading platform for the trade of financial assets including common stocks, preferred stocks, futures contracts, exchange-traded funds, options, cryptocurrency, mutual funds, and fixed income investments. It also provides margin lending, an…
Fidelity Investments
Fidelity Investments Inc., commonly referred to as Fidelity, earlier as Fidelity Management & Research or FMR, is an American multinational financial services corporation based in Boston, Massachusetts.
Full Answer
Should you hold Athersys (ATHX) stock?
The consensus among Wall Street research analysts is that investors should "hold" Athersys stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATHX, but not buy additional shares or sell existing shares. View analyst ratings for Athersys or view top-rated stocks.
Is Athersys efficiently growing its dividend?
Athersys does not have a long track record of dividend growth. In the past three months, Athersys insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,300.00 in company stock and sold $0.00 in company stock. 10.50% of the stock of Athersys is held by insiders.
What are analysts'target prices for Athersys'stock?
2 analysts have issued 12 month target prices for Athersys' shares. Their predictions range from $8.00 to $11.00. On average, they anticipate Athersys' stock price to reach $9.50 in the next year. This suggests a possible upside of 603.7% from the stock's current price.
Who is the new CEO of Athersys?
MarketWatchDow Jones Athersys Names Daniel Camardo as New CEO Jan. 20, 2022 at 6:21 p.m. ET Athersys Sees Positive Data in Trial for Acute Respiratory Distress Syndrome Treatment
Should I buy or sell Athersys stock right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 sell rating for the stock...
What is Athersys' stock price forecast for 2022?
1 brokers have issued 12 month target prices for Athersys' shares. Their forecasts range from $0.25 to $0.25. On average, they anticipate Athersys'...
How has Athersys' stock price performed in 2022?
Athersys' stock was trading at $0.9026 at the beginning of 2022. Since then, ATHX shares have decreased by 62.5% and is now trading at $0.3384. Vi...
When is Athersys' next earnings date?
Athersys is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Athersys .
How were Athersys' earnings last quarter?
Athersys, Inc. (NASDAQ:ATHX) released its earnings results on Friday, May, 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter....
Who are Athersys' key executives?
Athersys' management team includes the following people: Mr. William Lehmann Jr. , J.D., M.B.A., MBA, Pres, COO & Sec. (Age 56, Pay $533.6k) ( L...
What is Gil Van Bokkelen's approval rating as Athersys' CEO?
2 employees have rated Athersys CEO Gil Van Bokkelen on Glassdoor.com . Gil Van Bokkelen has an approval rating of 100% among Athersys' employees....
Who are some of Athersys' key competitors?
Some companies that are related to Athersys include Radius Health (RDUS) , OrganiGram (OGI) , Generation Bio (GBIO) , Vaxxinity (VAXX) , Affim...
What other stocks do shareholders of Athersys own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO...
About Athersys
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.
Headlines
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year? - Nasdaq
Athersys (NASDAQ:ATHX) Frequently Asked Questions
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Athersys stock.
Signals & Forecast
The Athersys stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $0.89 and $0.89.
Support, Risk & Stop-loss
Athersys finds support from accumulated volume at $0.88 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Athersys stock A Buy?
Athersys holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Insiders are very positive buying more shares than they are selling in Athersys
In the last 100 trades there were 26.47 million shares bought and 725.33 thousand shares sold. The last trade was done 11 days ago by Camardo Daniel A. who bough 4 million shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
About Athersys
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Is Athersys, Inc. (ATHX) Stock Outpacing Its Medical Peers This Year?
Here is how Athersys, Inc. (ATHX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.
Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635 (c) (4)
CLEVELAND, February 17, 2022--Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635 (c) (4). Stock Option Award Offered to Daniel Camardo, new Chief Executive Officer.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
ATHX POWR Grades
Growth is the dimension where ATHX ranks best; there it ranks ahead of 81.8% of US stocks.
ATHX Stock Summary
Of note is the ratio of Athersys Inc's sales and general administrative expense to its total operating expenses; merely 10.16% of US stocks have a lower such ratio.
ATHX Valuation Summary
ATHX's price/sales ratio is 280.3; this is 2369.6% higher than that of the median Healthcare stock.
ATHX Growth Metrics
Its 2 year net cashflow from operations growth rate is now at -72.37%.
ATHX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Latest ATHX News From Around the Web
Below are the latest news stories about Athersys Inc that investors may wish to consider to help them evaluate ATHX as an investment opportunity.
Athersys, Inc. - Buy
Zacks' proprietary data indicates that Athersys, Inc. is currently rated as a Zacks Rank 2 and we are expecting an above average return from the ATHX shares relative to the market in the next few months. In addition, Athersys, Inc.
Style Scorecard
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
Chart for ATHX
Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine.